SCHEMBL3402181

SCHEMBL3402181

CCOC(=O)c1sc(Cl)nc1-c1nnco1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 4/20 0.43
MAPT P10636 2/20 0.43
ALDH1A1 P00352 4/20 0.41
HSD17B10 Q99714 1/20 0.41
KDM4E B2RXH2 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
PPARG P37231 1/20 0.40
NCOA2 Q15596 1/20 0.40
NCOA1 Q15788 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
CDC7 O00311 7/20 0.40
DBF4 Q9UBU7 7/20 0.40
DHODH Q02127 3/20 0.40
HPGD P15428 1/20 0.40
RAB9A P51151 1/20 0.39
CYP1A2 P05177 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3401994 0.79 TRPM8 (0.42) TRPM8MAPTALDH1A1HSD17B10KDM4E
SCHEMBL3403879 0.76 TRPM8 (0.42) TRPM8MAPTALDH1A1HSD17B10KDM4E
SCHEMBL11159408 0.75 MAPT (0.62) TRPM8MAPTALDH1A1HSD17B10KDM4E
SCHEMBL3893108 0.75 ALDH1A1 (0.71) TRPM8ALDH1A1HSD17B10KDM4EMEN1
SCHEMBL1505433 0.75 LMNA (0.48) TRPM8MAPTALDH1A1HSD17B10MEN1
SCHEMBL11281010 0.73 ALDH1A1 (0.55) TRPM8ALDH1A1HSD17B10MEN1KMT2A
SCHEMBL11152604 0.73 TRPM8 (0.60) TRPM8MAPTALDH1A1HSD17B10KDM4E
SCHEMBL11279731 0.73 CDC7 (0.69) MAPTALDH1A1HSD17B10KDM4EMEN1
SCHEMBL187316 0.73 ALDH1A1 (0.59) MAPTALDH1A1HSD17B10KDM4EMEN1
SCHEMBL28049117 0.73 ALDH1A1 (0.50) TRPM8MAPTALDH1A1HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2158199-B1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2010-11-17 EP disclosed
EP-2158199-B1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2010-11-17 EP disclosed
EP-2158199-A1 PIPERIDINE COMPOUNDS AND USES THEREOF AstraZeneca AB (SE) 2010-03-03 EP disclosed
WO-2008152418-A1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2008-12-18 WO disclosed
WO-2008152418-A1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2008-12-18 WO disclosed
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 ASTRAZENECA AB (SE) 2008-12-18 US disclosed
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 ASTRAZENECA AB (SE) 2008-12-18 US disclosed
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 ASTRAZENECA AB (SE) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 NISCH, PIR, QDPR TRPM8 2191/4885MAPT 2837/4885ALDH1A1 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.